David Dornan - 14 Mar 2022 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
Chief Scientific Officer
Signature
/s/ Joseph Ferra, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4
Filing time
16 Mar 2022, 17:46:43 UTC
Previous filing
23 Feb 2022
Next filing
10 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Employee Stock Option (right to buy) Award $0 +230,000 $0.000000 230,000 14 Mar 2022 Common Stock 230,000 $2.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on March 14, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date and is subject to acceleration in the event of a change in control of the Issuer.